Gemin X

Cephalon to acquire Gemin X

Wednesday, March 23, 2011

Pennsylvania-basedCephalon has signed a definitive merger agreement to acquire all of the outstanding capital stock of Gemin X Pharmaceuticals, a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, for $225 million cash on a cash-free, debt-free basis.

[Read More]